Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Inventiva Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Inventiva has a total shareholder equity of €-32.0M and total debt of €54.1M, which brings its debt-to-equity ratio to -168.8%. Its total assets and total liabilities are €69.6M and €101.6M respectively.

Anahtar bilgiler

-168.8%

Borç/özkaynak oranı

€54.08m

Borç

Faiz karşılama oranı	n/a
Nakit	€27.34m
Eşitlik	-€32.03m
Toplam yükümlülükler	€101.59m
Toplam varlıklar	€69.56m

Son finansal sağlık güncellemeleri

Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt

Jun 15

Recent updates

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Sep 27

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Jun 18

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Jun 14

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

Mar 19

Here's What Inventiva S.A.'s (EPA:IVA) Shareholder Ownership Structure Looks Like

Jan 29

Is Inventiva's (EPA:IVA) 223% Share Price Increase Well Justified?

Dec 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IVA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Uzun Vadeli Yükümlülükler: IVA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IVA has negative shareholder equity, which is a more serious situation than a high debt level.

Borcun Azaltılması: IVA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IVA şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: IVA tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Inventiva Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt

Recent updates

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Price target decreased by 20% to €10.64

Consensus revenue estimates increase by 113%

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Consensus revenue estimates decrease by 67%

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Consensus revenue estimates decrease by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S

Consensus EPS estimates fall by 13%

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Price target decreased by 14% to €15.35

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Price target decreased by 7.4% to €16.50

New major risk - Negative shareholders equity

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 216%

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 78%

New major risk - Financial position

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 19%

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Consensus revenue estimates increase by 573%

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Price target increased by 15% to €18.76

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Analyst Forecasts Just Became More Bearish On Inventiva S.A. (EPA:IVA)

Consensus revenue estimates decrease by 15%

Pinning Down Inventiva S.A.'s (EPA:IVA) P/S Is Difficult Right Now

Consensus revenue estimates decrease by 37%

Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Consensus revenue estimates increase by 10%

Consensus revenue estimates increase by 352%

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt

Price target decreased to €19.96

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Forecast to breakeven in 2024

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.29 loss in 2Q 2020)

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

First quarter 2021 earnings released: €0.23 loss per share (vs €0.23 loss in 1Q 2020)

Price target increased to €26.59

Price target increased to €29.26

Here's Why Inventiva S.A.'s (EPA:IVA) CEO May Deserve A Raise

Did Business Growth Power Inventiva's (EPA:IVA) Share Price Gain of 251%?